|

Letermovir Clinical Trials

3 actively recruiting trials across 2 locations

Also known as: 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic Acid, AIC246, Elranatamab, MK-8228, Prevymis

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 1

Top Sponsors

  • Seoul National University Hospital1
  • City of Hope Medical Center1
  • Children's Oncology Group1

Indications

  • Cancer3
  • Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive1
  • Relapsed Refractory Multiple Myeloma (RRMM)1
  • Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive1
  • Myelofibrosis1

Other1 trial

Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy
Phase 2

Birmingham, Alabama1 trial

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

Children's Hospital of Alabama

Phase 3

Duarte, California1 trial

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

City of Hope Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.